MAIA Biotechnology Inc MAIA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.41
- Day Range
- $1.36–1.41
- 52-Week Range
- $0.87–3.19
- Bid/Ask
- $1.36 / $1.39
- Shares Outstanding
- 60.83M
- Market Cap
- $83.91M
- Volume/Avg
- 276,270 / 689,491
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 13
- Website
- https://www.maiabiotech.com
Valuation
|
Metric
|
MAIA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.06 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
MAIA
|
|---|---|
Quick Ratio | 4.41 |
Current Ratio | 4.51 |
Interest Coverage | — |
Quick Ratio
MAIA
Profitability
|
Metric
|
MAIA
|
|---|---|
Return on Assets (Normalized) | −129.20% |
Return on Equity (Normalized) | −226.85% |
Return on Invested Capital (Normalized) | −231.42% |
Return on Assets
MAIA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|^>b%#h | LOCK|Qv^s | $134B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|K^gZd># | LOCK|@?lR | $82B | |||
| argenx SE ADR
ARGX
| LOCK|B^<fSG | LOCK|R@ | $54B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|w>Cg$b^ | LOCK|?p#^< | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|L$LQc? | LOCK|Vj | $43B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|<#q%&$ | LOCK|h?@^b | $30B | |||
| Incyte Corp
INCY
| LOCK|L@#hNW | LOCK|pK | $25B | |||
| Moderna Inc
MRNA
| LOCK|F%%$qSZ | LOCK|LsJ | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|FKZ$Cf | LOCK|sx | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|^n&$<<j | LOCK|## | $16B |
United States